Abstract 1232P
Background
Randomized controlled trials (RCTs) showed survival improvement with neoadjuvant/perioperative ICI + CT in early NSCLC. However, interpretation of the results can be affected by a variable level of uncertainty due to censoring imbalance and vulnerability of statistical conclusions.
Methods
PubMed, Embase and Cochrane were searched until April 2024 for RCTs comparing neoadjuvant/perioperative ICI + CT with neoadjuvant CT in patients with early-stage NSCLC. Individual Patient Data (IPD) curves and the corresponding hazard ratios (HR) were reconstructed from published EFS Kaplan-Meier data from each trial and treatment arm by using an IPD software. Reverse HR (R-HR) was obtained by flipping the status of time-dependent outcome for individual patients (reverse Kaplan Meier method) and were used to estimate censoring imbalance. SIFI was determined by iteratively transferring the best survivors from the experimental arm to the control arm until p≥0.05; conversely, negative SIFI was calculated until p<0.05.
Results
Eight RCTs (n=3387) were included. R-HR analysis showed a trend in increased censoring imbalance in the experimental arm in 1 RCT (NADIM II) and in the control arm in 2 RCTs (NeoTORCH, TD-FOREKNOW), in 1 RCT (RATIONALE-315) censoring imbalance was significantly higher in the control arm (R-HR 1.30; 95% CI 1.02-1.65). Median SIFI was 12 (IQR, 4.25 - 20.25), with absolute weighted SIFI ≤ 2% in 3 RCTs (NADIM II, AEGEAN, Checkmate 816), suggesting a potential vulnerability affecting the significance of results. Table: 1232P
| Study name | N | IPD-HR | R-HR (control vs experimental) | SIFI (%) | Median FUP months (range, if specified) |
| AEGEAN | 740 | 0.70 (0.54 - 0.91) | 0.96 (0.80 - 1.15) | 9 (1) | 11.7 |
| NADIM II | 86 | 0.43 (0.21 - 0.86) | 0.51 (0.23 - 1.13) | 2 (2) | 26.1 (17.4 - 30.9) |
| CheckMate 816 | 358 | 0.66 (0.48-0.91) | 1.06 (0.80 - 1.41) | 5 (1) | 41.4 |
| NeoTORCH | 404 | 0.39 (0.28 - 0.54) | 1.12 (0.86 - 1.47) | 33 (8) | 18.3 |
| KEYNOTE 671 | 797 | 0.57 (0.46 - 0.70) | 0.99 (0.81 - 1.19) | 37 (5) | 25.2 (7.5 - 50.6) |
| CheckMate 77T | 461 | 0.58 (0.44 - 0.78) | 1 (0.78 - 1.28) | 15 (3) | 25.4 (15.7 - 44.2) |
| TD-FOREKNOW | 88 | 0.53 (0.21 - 1.30) | 1.33 (0.81 - 2.19) | -4 (5) | 14.1 (9.2 - 20.9) |
| RATIONALE-315 | 453 | 0.56 (0.40 - 0.79) | 1.30 (1.02 - 1.65) | 16 (4) | 22.0 |
Conclusions
Significant censoring imbalance in the control arm and high survival fragility were reported in 1 and 3 RCTs, respectively, suggesting that informative censoring and survival vulnerability are useful tools to ensure a reliable interpretation of data.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1131P - A phase II study of pembrolizumab combination with temozolomide as 1L treatment for Chinese metastatic acral melanoma patients
Presenter: Ya Ding
Session: Poster session 04
1132P - Regorafenib in Caucasian patients with pretreated advanced KIT-mutant melanoma: A dual center case series
Presenter: Iris Dirven
Session: Poster session 04
1133P - Only early adjuvant radiotherapy, particularly of the tumor bed rather than the lymph node region, improves prognosis in Merkel cell carcinoma: Results from the prospective German MCC registry
Presenter: Juergen Becker
Session: Poster session 04
1134P - Avelumab in metastatic Merkel cell carcinoma (mMCC): Conditional survival and long-term safety in patients treated for ≥1 or ≥2 years in JAVELIN Merkel 200
Presenter: Celeste Lebbe
Session: Poster session 04
1135P - Multi-modal and longitudinal characterization of the tumor and immune microenvironment of Merkel cell carcinoma
Presenter: Maximilian Haist
Session: Poster session 04
1136P - Cosibelimab in advanced cutaneous squamous cell carcinoma (CSCC): Longer-term efficacy and safety results from pivotal study
Presenter: Eva Muñoz-Couselo
Session: Poster session 04
1137P - Efficacy of LNS8801 in melanoma patients with prior immune-related adverse events from immune-checkpoint inhibitors
Presenter: Justine Cohen
Session: Poster session 04
1138P - A prospective study of patients with immune checkpoint inhibitor-induced hepatitis: Management outcome and association with liver injury subtype, immune infiltration, and clinical parameters
Presenter: Rikke Holmstroem
Session: Poster session 04
1139TiP - IDE196 (darovasertib) in combination with crizotinib versus investigator’s choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma
Presenter: Marcus Butler
Session: Poster session 04
1140TiP - Safe stop IPI-NIVO trial: Early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab
Presenter: Joséphine Janssen
Session: Poster session 04